Open Access


Read more
image01

Online Manuscript Submission


Read more
image01

Submitted Manuscript Trail


Read more
image01

Online Payment


Read more
image01

Online Subscription


Read more
image01

Email Alert



Read more
image01

Original Research Article | OPEN ACCESS

Erratum “Loureirin B attenuates amiodarone-induced pulmonary fibrosis by suppression of TGFβ1/Smad2/3 pathway”

Weixiu Ma1, Haixia Shi2, Guangming Wei3, Mao Hua1, Jinhua Ma4, Jinxia Cui1, Honggang Yu5

1Department of Respiratory Medicine, Affiliated Hospital of Qinghai University; 2Department of Emergency Medical, Affiliated Hospital of Qinghai University, Xining City, Qinghai Province 810000; 3Department of Nuclear Medicine, The Second Affiliated Hospital of Air Force Military Medical University, Xi'an City, Shaanxi Province 710038; 4Department of Oncology, Affiliated Hospital of Qinghai University, Xining City, Qinghai Province 810000; 5Department of Pulmonary Disease, Xi’an Hospital of Traditional Chinese Medicine, Xi'an City, Shaanxi Province 710000, China.

For correspondence:-  Honggang Yu   Email: GHY76Ykju@163.com   Tel:+862989626831

Accepted: 22 June 2020        Published: 30 November 2020

Citation: Ma W, Shi H, Wei G, Hua M, Ma J, Cui J, et al. Erratum “Loureirin B attenuates amiodarone-induced pulmonary fibrosis by suppression of TGFβ1/Smad2/3 pathway”. Trop J Pharm Res 2020; 19(11):2477-2477 doi: 10.4314/tjpr.v19i11.31

© 2020 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Erratum
 
Ma et al. Loureirin B attenuates amiodarone-induced pulmonary fibrosis by suppression of TGFβ1/Smad2/3 pathway. Trop J Pharm Res 2020; 19(7):1371-1376 doi: http://dx.doi.org/ 10.4314/tjpr.v19i7.5
 
Authors’ addresses: The correct addresses of the authors are the ones provided above.  
Contribution of authors: Weixiu Ma and Haixia Shi contributed equally to the work.
 
Citation: Ma W, Shi H, Wei G, Hua M, Ma J, Cui J. Loureirin B attenuates amiodarone-induced pulmonary fibrosis by suppression of TGFβ1/Smad2/3 pathway. Trop J Pharm Res 2020; 19(7):1371-1376 doi: http://dx.doi.org/10.4314/tjpr.v19i7.5. Erratum: 2020; 19(11):2477 http://dx.doi.org/ 10.4314/tjpr.v19i11.31

Keywords: Amiodarone, Loureirin B, Pulmonary fibrosis, Smad, Inflammation

Impact Factor
Thompson Reuters (ISI): 0.6 (2023)
H-5 index (Google Scholar): 49 (2023)

Article Tools

Share this article with



Article status: Free
Fulltext in PDF
Similar articles in Google
Similar article in this Journal:

Archives

2024; 23: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10. 
2023; 22: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2022; 21: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2021; 20: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2020; 19: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2019; 18: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2018; 17: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2017; 16: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2016; 15: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2015; 14: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2014; 13: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2013; 12: 
1,   2,   3,   4,   5,   6. 
2012; 11: 
1,   2,   3,   4,   5,   6. 
2011; 10: 
1,   2,   3,   4,   5,   6. 
2010; 9: 
1,   2,   3,   4,   5,   6. 
2009; 8: 
1,   2,   3,   4,   5,   6. 
2008; 7: 
1,   2,   3,   4. 
2007; 6: 
1,   2,   3,   4. 
2006; 5: 
1,   2. 
2005; 4: 
1,   2. 
2004; 3: 
1. 
2003; 2: 
1,   2. 
2002; 1: 
1,   2. 

News Updates